Alza Corporation

Groupon, Inc.

Suneel K Gupta

Lawrence G Hamel

Diane R Guinta

Carol A Christopher

Samuel R Saks

Ronald P Haak

Felix T Theeuwes

Atul D Ayer

Gary A Lattin

J Bradley Phipps

Andrew C Lam

Jeri D Wright

Padmaja Shivanand

Zahedeh Hatamkhany

Richard G Weyers

Robert M Gale

Michel J N Cormier

Patricia S Campbell

Melinda K Nelson

Gayatri Sathyan

Jeffrey Alan Holden

Don Albert Chennavasin

Amit Aggarwal

David Thacker

Mihir Shah

Yishai Lerner

Noymi Yam

Andrew Mason

Rama V Padmanabhan

Scott Bull

Rhea Donley

Nishit Modi

Brian M Stolte

Brett R Keintz

Iran Reyes

David Jesse

Nyomi V Yam

Dan Nawara

Julie Lee

Sonya Seroff

In a promotion offering system, a consumer is more likely to purchase a promotion offering if the consumer finds the promotion to be interesting or fits a need of the consumer. In order to provide a more intelligent selection process for selecting promotions that are desirable to the consumer, a method and a promotion offering system for implementing the method are provided that takes into consideration a number of different factors associated with a consumer, including locations and deal types that are known or predicted to be of interest to the consumer, when determining one or more promotions to present to the consumer.

Promotion offering system

Dosage forms and methods for providing a substantially ascending rate of release of paliperidone or risperidone are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma paliperidone or risperidone concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plasma paliperidone or risperidone concentration occurrence in each 24 hour period. In addition, the peak plasma paliperidone or risperidone concentration occurs at a later time following dose administration and exhibits a lesser magnitude than the peak plasma paliperidone or risperidone concentration that occurs following administration of paliperidone or risperidone in an immediate-release dosage form.

Methods and dosage forms for controlled delivery of paliperidone and risperidone

Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.

Methods and devices for providing prolonged drug therapy

Systems and methods are disclosed that provide offers for goods or services based on the locations of potential customers and the geographic locations of the merchant. The offers may be limited in quantity and acceptance and redemption of the offers may be limited in time. A unique identifier may be associated with each accepted offer. A merchant may have at least some control over the creation and rendering of one or more offers for the merchant's goods and services.

System and methods for providing location based discount retailing

The present invention relates to a novel controlled release formulations of tizanidine. The invention also provides methods of using novel controlled release formulations of tizanidine to treat a patient.

Controlled release compositions of tizanidine

A method of increasing the delivery efficiency of an agent through a body surface by electrotransport is disclosed wherein the electrotransport current is applied for durations at a higher current density values followed by durations of lower current density values wherein the higher current density applications transform the body surface to an enhanced, non-transitory agent delivery efficiency state.

Electrotransport agent delivery method and apparatus

An electrotransport agent delivery device () for delivering a therapeutic agent through intact skin, and a method of operating same, is provided. The device applies a pulsing electrotransport current wherein current pulses have a magnitude above a critical level (I) at which the skin is transformed into a higher electrotransport delivery efficiency (E) state. Most preferably the length of the applied current pulses is at least 5 msec and preferably at least 10 msec.

An electrotransport agent delivery device () for delivering a therapeutic agent through intact skin, and a method of operating same, is provided. The device applies a pulsing electrotransport current wherein the length of the applied current pulses is at least 5 msec and preferably at least 10 msec. Most preferably, the current pulses have a magnitude above a critical level (I) at which the skin is transformed into a higher electrotransport delivery efficiency (E) state.

Electrotransport agent delivery apparatus

Composition of matter for application to a body surface or membrane to administer fluoxetine by permeation through the body surface or membrane, the composition comprising fluoxetine to be administered, at a therapeutically effective rate, alone or in combination with a permeation enhancer or mixture. A preferred embodiment is directed to the transdermal administration of fluoxetine at reduced skin irritation levels wherein fluoxetine, preferably provided as fluoxetine acetate, is coadministered with a corticosteroid such as hydrocortisone. Also disclosed are drug delivery devices containing the fluoxetine or fluoxetine and enhancer composition and methods for the transdermal administration of the fluoxetine and fluoxetine/enhancer composition.

Formulations for the administration of fluoxetine

Growing community of inventors

Sunnyvale, CA, United States of America

Suneel K Gupta